
# RECEIVED CENTRAL FAX CENTER





# FACSIMILE TRANSMITTAL SHEET

Today's Date: January 4, 2005

Time: 4:16 PM

Employee ID: 6604

# of Pages: 73

From: Deborah A. Miller, Ph.D.

Direct Dial: 617-439-2863

Fax No: 617-310-9863

RECIPIENT	COMPANY	FAX No. Phone No.		
	USPTO			

# **COMMENTS:**

Re: Application No. 10/766,642

Title: Enhancement of Angiogenesis To Grafts Using Cells Engineered to Produce

Growth Factors

Filing Date: January 28, 2004

Group Art Unit: 1651 Examiner; A. Ford

Please see attached Information Disclosure Statement regarding the above-referenced application.

1392517.1

STATEMENT OF CONFIDENTIALITY

The documents included with this facsimile transmittal sheet contain information from the law firm of Nutter McClemen & Fish LLP which is confidential and/or privileged. The information is intended to be for the use of the addressee named on this transmittal sheet. If you are not the addressee, note that any disclosure, photocopying, distribution or use of the contents of this faxed information is prohibited. If you have received this facsimile in error, please notify us by telephone (collect) immediately so that we can arrange for the retrieval of the original documents at no cost to you.

IF THERE IS A PROBLEM WITH THIS TRANSMISSION, OR IF YOU DID NOT RECEIVE ALL PAGES, PLEASE CALL 617-439-2676, AS SOON AS POSSIBLE

FOR NUTTER McCLENNEN & FISH LLP USE ONLY

Client-Matter No.

Nutter McClennen & Fish LLP - Attomeys at Law

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Anthony Atala et al.

Application No.: 10/766,642 - 4621

Group Art Unit: 1651

Filed: January 28, 2004

Examiner: A. Ford

For

Enhancement of Angiogenesis To Grafts Using Cells Engineered To Produce Growth Factors

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### TRANSMITTAL LETTER

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

- 1. Information Disclosure Statement; and
- 2. PTO/SB/08 Form cited (23) references thereon.

The Commissioner is authorized to charge any overpayments or underpayments if necessary to our Deposit Account No. 141449, Reference No. 105447-2, Customer No. 021125. A duplicate of this sheet is enclosed.

I hereby cartify that this correspondence is being

sent via facsimile at 571-273-8300 to:

Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450 on:

January 4, 2005

Date

Deborah A. Miller, Reg. No 53,328

Respectfully submitted.

Deborah A. Miller, Reg. No. 53,328

Agent For Applicants

NUTTER MCCLENNEN & FISH, LLP

World Trade Center West

155 Seaport Bouleyard

Boston, Massachusetts 02210-2604

Tel, (617) 439-2863

Fax (617) 310-9863

1391970.1

JAN 0 4 2005

Attorney Docket No.: 105447-2

NO.906 P.3

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Anthony Atala et al.

Application No.: 10/766,642 - 4621

Group Art Unit: 1651

Filed: January 28, 2004

Examiner: A. Ford

For:

Enhancement of Angiogenesis To Grafts Using Cells Engineered To Produce Growth Factors

# Certificate of Facsimile

I hereby certify that this correspondence is being sent via facsimile to: Commissioner for Patents, P.Q. Box 1450. Alexandria, VA 22313-1450 at 571-273-8300 on:

January 4, 2005

Deborah A. Miller

Date of Signature and

Transmission

Reg. No: 53,328

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56, §1.97 and §1.98, Applicants herewith make of record the reference listed on the attached copy of PTO/SB/08A Form. In accordance with §1.97(b), this statement is being filed before the mailing of a first Office Action.

Applicants have not submitted copies of each cited U.S. patent and each U.S. patent application as required by 37 C.F.R. 1.98 (a)(2)(i) since the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. If a copy of any cited reference is needed, please call the undersigned at the telephone number indicated below.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed per se as a representation

that such publication is prior art. Moreover, the Applicants understand the Examiner will make an independent evaluation of the cited publications.

Accordingly, no additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 141449.

Dated: January 4, 2005

Respectfully submitted,

Deborah A. Miller, Reg. No. 53,328

Agent For Applicants

Nutter, McClennen & Fish, LLP

World Trade Center West

155 Seaport Boulevard

Boston, MA 02210-2604 Tel. (617) 439-2863

Fax. (617) 310-9863

1391962.1

PTCYSB/tbs//b (08-03)
Approved for Use through 07/31/2006, OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1895, no persons are required to respond to g collection of information unless a combine a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete If Known				
				Application Number	10/766,642	
INFORMATION DISCLOSURE				Filing Date	January 28, 2004	
S	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	Anthony Atala et al.	
				Art Unit	1651	
				Examiner Name	A. Ford	
Sheet	1	of	1	Attemey Desket Number	105447-2	

			U.S.	PATENT DO	CUMENTS		
Examiner initals*	Cite No.	Document Number Number-Kind Code <sup>2</sup> ( # Known)	Publication D MM-DO-YY	êta -	Name of Patentee or pplicant of Cited Document	Pages, Columns, Lines, Who Rolcvant Passages or Relev Figures Appear	ere rent
	AA	6,753,181	06/22/200	4 Atala			
	AB	6,673,339	01/06/200	4 Atala et a	1.		
	AC	6,620,203	09/18/200	3 Atala		• "	
	AD	6,576,019	06/10/200	3 Atala			
	AÉ	6,519,492	02/11/200	3 Yoo et al.			
	AF	6,482,645	11/19/200				
	AG	6,479,064	11/12/200			• • • • • • • • • • • • • • • • • • • •	
	AH	8,432,081	08/13/200				
	ΑI	6,428,802	08/06/200	2 Atala			
	ΑJ	6,383,478	05/07/200	2 Prokop e	t al.	,	_
	AK	6,376,244	04/23/200	2 Atala			
	AL	6,171,344	01/09/200	1 Atala			
	AM	6,165,487	12/26/200	0 Ashkar et	t al.		
	AN	6,140,039	10/31/200	0 Naughtor	et al.		
	AO	5,858,721	01/12/199	9 Naughtor	et al.		
	AP	5,785,964	07/28/199	8 Naughtor	et al.		
	AQ	5,855,610	01/05/199		t si.		
	AR	5,851,833	12/22/199				
	AS	5,266,480	11/30/199	3 Naughtor	et al.		
			FOREIG	N PATENT	DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Docum Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Co		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Whore Relevant Passages or Relevant Figures Appear	₽
	BA	WO 02/073187		09/19/2002	Advanced Cell Technology, inc.		

IIIC.

EXAMINER: mital if reference considered, whether or not chapton is in conformance with MPEP 609. Draw line through cliation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (options), 2 See Kinds Codes of USPTO Patent Documents as www.uepto.gov or MPEP 601.04. Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Bæminer Initiels	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	CA	Cima, L.G. et al. "Tissue Engineering By Cell Transplantation Using Degradable Polymer Substrates", Journal of Biomechanical Engineering" Vol. 113, pg. 143-151 (1991);			
	CB	Lanza, Robert P. et al. "Generation of Histocompatible Tissues Using Nuclear Transplantation" Nature Biotechnology, Vol. 20, pg. 689-696 (2002).			
	CC	Schuch, Gunter et al. "In Vivo Administration of Vascular Endothelia! Growth Factor (VEGF) And its Antagonist, Soluble Neuropilin-1. Predicts A Role of VEGF in The Progression of Acute Myeloid Leukemia in Vivo", Blood, Vol. 100, No. 13, pg. 4622-4628 (2002);			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). "Applicant is to place a check mark here if English language Translation is attached.

Exeminer	Data	
Signature	Considered	